Small Biotech Enters Patent Deal with British Company Targeting Schizophrenia
Source: Streetwise Reports  (10/4/17)
A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.
More >

Biotech with Transformative RNAi Delivery System Set for Multiple Catalysts by Year-End
Source: Streetwise Reports  (10/4/17)
With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, Dr. Gerrit Dispersyn, RXi's Chief Development Officer, and Dr. Karen Bulock, Vice President of Research at RXi.
More >

Immunotherapy Firm's Technology Demonstrates 'Potential Use in Treating Cancers and Bacterial Infections'
Source: Streetwise Reports  (9/27/17)
H.C. Wainwright & Co. reported the results of animal studies conducted using therapeutics created by this cancer and chronic infectious disease vaccine developer. More >

Possible 'Best-in-Class' Alzheimer's Drug Candidate Offers 'Disruptive' Potential
Source: Streetwise Reports  (9/20/17)
André Uddin, an analyst with Mackie Research, explained the rationale for adding this neurodegenerative disease biotech company to his firm's coverage universe. More >

Gout, Kidney Stones, Liver Disease & Cannabinoids
Source: Danny Deadlock for Streetwise Reports  (9/15/17)
Danny Deadlock, founder of Microcap.com, profiles a company that is working on a novel drug delivery technology with a focus on cannabinoids for the potential to treat various major diseases. More >

Biopharma Gets Green Light for Hypertension Study
Source: Streetwise Reports  (9/13/17)
Jason McCarthy, an analyst at Maxim Group, discussed this France-based biotech firm's near-term clinical trial and catalysts. More >

Small-Cap Biotech Benefits from First FDA Approval of CAR-T Therapy
Source: Streetwise Reports  (9/1/17)
The first approval of a cell therapy for treatment of pediatric blood cancer prompted H. C. Wainwright to increase its price target for a UK-based biotech manufacturing one of the therapy's components.
More >

With Acquisition of Kite Pharma, Gilead Becomes a 'Major Player' in CAR-T Arena
Source: Streetwise Reports  (8/30/17)
Jason Kolbert, analyst with Maxim Group, assesses the billion-dollar transaction that would bring Kite Pharma and the earning potential of its cell therapy programs under the larger biotech's umbrella.
More >

Medical Cannabis Innovator Set to Go Public
Source: Streetwise Reports  (8/18/17)
A licensed producer of medical cannabis in Canada will begin trading on the Canadian Securities Exchange on Aug. 21. More >

Immunotherapy Company's Q2 Revenue 'Handily Beats' H.C. Wainwright's Projection
Source: Streetwise Reports  (8/16/17)
Analyst Ram Selvaraju with H.C. Wainwright & Co. provided an update on this biotech company's REVEAL clinical programs, as well as Q2/17 earnings that exceeded expectations.
More >

Maxim Raises Target Price of Biotech Company
Source: Streetwise Reports  (8/16/17)
A year-over-year increase in sales of its flagship product, and the prospect that its technology could be used to promote the efficacy of cell therapies, helped spur a target price increase on this biotech.
More >

Cell Therapy for Melanoma Impresses in
Phase 2
Source: Streetwise Reports  (8/9/17)
Positive clinical data for this U.S. company's immunotherapy for metastatic melanoma are both encouraging and impressive, says one analyst.
More >

Over-the-Counter Treatments for Joint Pain and Women's Health Propel Company into New Markets
Source: Streetwise Reports  (8/9/17)
With the launch of its over-the-counter combination treatment for joint pain and new licensing agreements for feminine lubrication product Zestra, this San Diego-based company is expanding both its therapeutic and international reach.
More >

Company Developing Cannabinoid-Based Drug Therapy for Concussions Completes Reverse Takeover
Source: Streetwise Reports  (8/7/17)
A drug developer working on a treatment for concussions expects to begin trading on the TSX Venture Exchange on Aug. 8. More >

This Just Changed Everything: Green Profits Are Being Unleashed
Source: Kenneth Ameduri for Streetwise Reports  (8/3/17)
Kenneth Ameduri, founder of Crush the Street, discusses why he believes now is a good time to take advantage of cannabis investing opportunities. More >

Canadian Medical Cannabis Provider Expanding into US Market Through RTO
Source: Streetwise Reports  (7/25/17)
A company with Canadian medical cannabis provider Aphria's backing is doing a reverse takeover on the Canadian Securities Exchange and expects to begin trading on July 26. More >

DNA-Based Compound Shuts Down Seasonal Flu in Preclinical Study
Source: Streetwise Reports  (7/19/17)
A U.S. biotech developing vaccines to fight a number of infectious diseases has generated promising preclinical results with a platform therapy targeting influenza, and expects to enter the clinic with a similar platform compound targeting Ebola in 2018. More >

Progress in Pain Control and Liver Disease Programs Spurs Rise in Company's Rating
Source: Streetwise Reports  (7/19/17)
News about progress in two of this biotech's development programs prompted a rating upgrade by analyst Adam Walsh of Stifel Nicolaus & Company. More >

Biotech with Alzheimer's Focus Makes Progress on Several Fronts
Source: Streetwise Reports  (7/18/17)
In its corporate update for Q2/17, a Canada-based biotech targeting neurological disorders including Alzheimer's disease informed investors of advancements in several programs, including designation of a second validated lead compound in development. More >

2017 Small-Cap Biotech Watchlist Update: Up 21% at the End of Q2/17
Source: Streetwise Reports  (7/13/17)
If an investor had purchased an equal dollar amount of each company on The Life Sciences Report's 2017 Small-Cap Biotech Watchlist at the beginning of the year, that portfolio would show a gain of about 21% as of July. This is primarily due to the performance of a handful of companies that have been moving their assets farther down the development pipeline, according to the analysts who follow them. More >

Multifaceted Biotech Company Poised to Begin Trading on Canadian Securities Exchange
Source: Streetwise Reports  (7/11/17)
A Vancouver-based biotech firm that aims to become the first preventative medicine company is expected to commence trading on the Canadian Securities Exchange July 14. More >

Analysts Take Note as Small-Cap Biotech Completes Early Enrollment for Phase 3 Trial
Source: Streetwise Reports  (7/5/17)
With enrollment complete in its Phase 3 trial of a compound that treats post-operative pain, and an infusion of cash from a new partnership with a major pharmaceutical corporation, one analyst has initiated coverage of this California-based company, and another has reiterated his investment thesis.
More >

Coverage Initiated on Synthetic Cannabinoid Bioscience Company, an 'Exciting, Undiscovered Story'
Source: Streetwise Reports  (6/29/17)
Laidlaw & Company initiated coverage with a Buy rating and target price of $18 on a company that is repurposing an approved cannabinoid to fulfill unmet medical needs. More >

With Completion of Offer, Analyst Says This Biotech Stock Could Triple
Source: The Life Sciences Report  (6/28/17)
A Canadian company with its lead drug candidate in a Phase 3 trial recently closed an offering that raised CA$10 million for future research, which has one analyst contemplating the potential for "3x upside." More >

Fast-Growing Pharma Company Prepares to Launch OTC Nasal Spray
Source: The Life Sciences Report  (6/21/17)
A San Diego-based pharmaceutical company that focuses on over-the-counter medications reported strong Q1/17 results and expects to begin marketing a nasal spray by the end of the year. More >